The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals

Grants

Funding Acknowledgements

ADDNEUROMED: AddNeuromed is supported by InnoMed (Innovative Medicines in Europe), an Integrated Project funded by the European Union of the Sixth Framework programme priority FP62004-LIFESCIHEALTH-5, Life Sciences, Genomics, and Biotechnology for Health.ADNI: ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and several generous contributions from the following: Alzheimer's Association, Alzheimer's Drug Discovery Foundation, BioClinica Inc., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai, Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc., GE Healthcare, Innogenetics NV, IXICO Ltd., Janssen Alzheimer Immunotherapy Research & Development LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Medpace Inc., Merck & Co. Inc. Meso Scale Diagnostics LLC, NeuroRx Research, Novartis Pharmaceuticals Corp., Pfizer Inc., Piramal Imaging, Servier, Synarc Inc. and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. Data collection and sharing for in ADNI were funded by the National Institutes of Health (NIH) (Grant U01 AG024904). ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH Grants P30 AG010129 and K01 AG030514.AIBL: The AIBL Research Group thanks all the participants who took part in the AIBL study and the clinicians who referred participants. The AIBL study (www.AIBL.csiro.au) is a collaboration between CSIRO, Edith Cowan University (ECU), The Florey Institute of Neuroscience and Mental Health (FINMH), National Ageing Research Institute (NARI), and Austin Health. It also involves support from CogState Ltd., Hollywood Private Hospital, and Sir Charles Gairdner Hospital. The study received funding support from CSIRO, the Science and Industry Endowment Fund (www.SIEF.org.au), NHMRC and Dementia Collaborative Research Centres (DCRC), Alzheimer's Australia (AA), Alzheimer's Association, and the McCusker Alzheimer's Research Foundation.BRC: Data acquisition and analysis were supported by funds from National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health and the NIHR Biomedical Research Unit for Dementia at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Kings College London. Co-authors AS and SL were also supported by funds from these institutions.BioFINDER: The study was supported by the European Research Council, the Swedish Research Council, the Strategic Research Programme in Neuroscience at Lund University (MultiPark), the Crafoord Foundation, the Swedish Brain Foundation, The Swedish Alzheimer foundation, the Torsten Soderberg Foundation at the Royal Swedish Academy of Sciences, and the regional agreement on medical training and clinical research (ALF) between Region Skane and Lund University.PIVUS: PIVUS was supported by AstraZeneca R&D Molndal and Uppsala University Hospital.SNAC-K: The Swedish National study on Aging and Care, SNAC (www.snac.org), is financially supported by the Ministry of Health and Social Affairs, Sweden, the participating County Councils and Municipalities, and the Swedish Research Council. We are grateful to the SNAC-K participants and to our colleagues in the SNAC-K group for their collaboration in data collection and management.